Short Interest in Genmab A/S (NASDAQ:GMAB) Drops By 6.4%

Genmab A/S (NASDAQ:GMAB) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,620,000 shares, a decrease of 6.4% from the January 15th total of 1,730,000 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 1.2 days.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of GMAB. Deep Track Capital LP purchased a new position in shares of Genmab A/S during the fourth quarter worth approximately $41,740,000. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth approximately $33,804,000. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after acquiring an additional 1,038,400 shares during the period. Two Sigma Investments LP increased its position in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after acquiring an additional 938,455 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after acquiring an additional 694,243 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average target price of $42.17.

Genmab A/S Stock Up 1.4 %

Genmab A/S stock traded up $0.30 during midday trading on Tuesday, reaching $21.60. The stock had a trading volume of 1,095,717 shares, compared to its average volume of 1,563,852. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The firm has a market cap of $14.29 billion, a price-to-earnings ratio of 20.97, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The company has a fifty day moving average of $20.64 and a 200 day moving average of $23.02.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Equities research analysts predict that Genmab A/S will post 1.25 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.